Successful treatment of SAPHO syndrome with an oral bisphosphonate

Rheumatology International

Volumn 29, Issue 6, 2009, Pages 713-715

  Ichikawa, Jiro ^a   Sato, Eiichi ^a   Haro, Hirotaka ^a   Ando, Takashi ^a   Maekawa, Singo ^a   Hamada, Yoshiki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Bisphosphonate; Complications; SAPHO syndrome; Therapeutic efficacy

Indexed keywords

ALENDRONIC ACID; CORTICOSTEROID; DICLOFENAC; ERYTHROMYCIN; LOXOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADULT; ANAMNESIS; ARTICLE; BONE SCINTISCANNING; CASE REPORT; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SAPHO SYNDROME; X RAY;

ACNE VULGARIS; ADMINISTRATION, ORAL; DIPHOSPHONATES; FEMALE; FEMUR; FOLLOW-UP STUDIES; HUMANS; HYPEROSTOSIS; MIDDLE AGED; OSTEITIS; SYNDROME; SYNOVITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 63349095496     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-008-0760-z     Document Type: Article

References (12)

1. I Olivieri A Padula C Palazzi 2006 Pharmacological management of SAPHO syndrome Expert Opin Investig Drugs 15 1229 1233 10.1517/13543784.15.10.1229
2. H Amital YH Applbaum S Aamar N Daniel A Rubinow 2004 SAPHO syndrome treated with pamidronate: an open-label study of 10 patients Rheumatology (Oxford) 43 658 661 10.1093/rheumatology/keh149
3. C Kerrison JE Davidson AG Cleary MW Beresford 2004 Pamidronate in the treatment of childhood SAPHO syndrome Rheumatology (Oxford) 43 1246 1251 10.1093/rheumatology/keh295
4. A Fioravanti L Cantarini L Burroni MA Mazzei L Volterrani M Galeazzi 2008 Efficacy of alendronate in the treatment of the SAPHO syndrome J Clin Rheumatol 14 183 184 10.1097/RHU.0b013e318177a64f
5. N Pennanen S Lapinjoki A Urtti J Mönkkönen 1995 Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro Pharm Res 12 916 922 10.1023/A: 1016281608773
6. JJ Body 2006 Breast cancer: bisphosphonate therapy for metastatic bone disease Clin Cancer Res 12 20S 6258 6263 10.1158/1078-0432.CCR-06-0840
7. LS Rosen D Gordon M Kaminski A Howell A Belch J Mackey 2003 Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 1735 1744 10.1002/cncr.11701
8. A Bamias E Kastritis C Bamia LA Moulopoulos I Melakopoulos G Bozas 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors J Clin Oncol 23 8580 8587 10.1200/JCO.2005.02.8670
9. SL Ruggiero B Mehrotrs TJ Rosenberg SL Engroff 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases J Oral Maxillofac Surg 62 527 534 10.1016/j.joms.2004.02.004
10. JJ Body 2001 Dosing regimens and main adverse events of bisphosphonates Semin Oncol 28 49 53 10.1016/S0093-7754(01)90232-5
11. S Uchida T Taniguchi T Shimizu T Kakikawa K Okuyama M Okaniwa 2005 Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study J Bone Miner Metab 23 382 388 10.1007/s00774-005-0616-5
12. E Solau-Gervais M Soubrier I Gerot L Grange X Puechal C Sordet 2006 The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome Rheumatology (Oxford) 45 339 342 10.1093/rheumatology/kei160